HIMS·Hims & Hers Health, Inc.

Hims & Hers (HIMS) is acquiring Eucalyptus, an Australian digital health firm, in a deal valued at $1.15 billion, a move that is expected to expand its global footprint and telehealth offerings. This acquisition, announced within the last day, signals a strong push into the telehealth market and could reshape HIMS's market positioning, potentially leading to increased revenue growth. The deal is expected to accelerate HIMS's expansion, including into Australia and Japan, and is seen as a positive catalyst for growth. However, the company faces scrutiny regarding its weight-loss drugs, FDA review, and a patent lawsuit from Novo Nordisk, which could cloud earnings. Analysts anticipate declining earnings per share, despite projected revenue increases. Investors should watch for updates during the upcoming earnings call, as significant stock volatility is anticipated.